Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT03829384 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of mRNA-1944 in Healthy Adults | PHASE1 | COMPLETED | 39 | — | — | Jan 22, 2019 | Jun 7, 2021 | Jul 7, 2021 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| mRNA-1944 | EXPERIMENTAL | Escalating dose levels |
| Placebo | PLACEBO_COMPARATOR | Saline |
| Name | Type | Description |
|---|---|---|
| mRNA-1944 | BIOLOGICAL | mRNA encoding Chikungunya antibody |
| Placebo | OTHER | Saline |
Inclusion Criteria: * Male or female ≥ 18 and ≤ 50 years of age * Weight of 50 to 100 kg, inclusive * In good general health as determined by medical history, clinical laboratory assessments, ECG results, vital sign measurements, and physical examination findings at screening * Has access to consis...